Crossmark

Elevated HMGB1 promotes the malignant progression and contributes to cisplatin resistance of non-small cell lung cancer

Published Online: 2023-07-31

Authors

Ma, Ying

Feng, Qin

Han, Bateer

Yu, Rong

Jin, Zhiyong http://orcid.org/0000-0003-2808-5934
Funding

Funding for this research was provided by:

Autonomous region health science and technology plan projects of Health Commission of Inner Mongolia（2022) (202201289)

Autonomous region health science and technology plan projects of Health Commission of Inner Mongolia（2022） (202201363)

Million-dollar joint projects of Inner Mongolia Medical University (YKD2021LH035)
License Information

Text and Data Mining valid from 2023-07-31

Version of Record valid from 2023-07-31
More Information

Article History

Received: 17 May 2023

Accepted: 17 July 2023

First Online: 31 July 2023

Declarations

:

: Our study was approved by ethic committee of Affiliated Hospital of Inner Mongolia Medical University and Nanfang Hospital of Southern Medical University, in accordance with The Helsinki Declaration. All participants have provided the informed consents.

: Not applicable.

: The authors declare that there is no competing interest regarding the publication of this paper.

Document is current